# A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

> **NCT03879122** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 135 (estimated)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer

## Interventions

- **DRUG:** Ipilimumab 5 MG/ML
- **DRUG:** Nivolumab 10 MG/ML
- **DRUG:** Docetaxel
- **DRUG:** ADT (androgen deprivation therapy)

## Key facts

- **NCT ID:** NCT03879122
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-11
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2022-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03879122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03879122, "A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03879122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*